We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$314M
AUM Growth
-$9.85M
Cap. Flow
-$5.57M
Cap. Flow %
-1.77%
Top 10 Hldgs %
94.94%
Holding
14
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$3.17M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$8.74M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$13

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
1
Gossamer Bio
GOSS
$66.5M
$95.6M 30.44%
6,119,345
-433,771
-7% -$8.74M
REPL icon
2
Replimune Group
REPL
$814M
$76.1M 24.24%
5,323,455
+220,000
+4% +$3.17M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$51M 16.22%
2,969,582
– –
TBIO
4
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$19.8M 6.32%
2,437,603
– –
IMUX icon
5
Immunic
IMUX
$182M
$13.3M 4.23%
137,149
– –
PRVL
6
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$10.6M 3.37%
668,907
-1
-0% -$13
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.5M 3.34%
2,600,410
– –
EPIX
8
DELISTED
ESSA Pharma
EPIX
$9.4M 2.99%
1,709,848
– –
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$6.3M 2.01%
82,026
– –
KYNB
10
Kyntra Bio
KYNB
$28.5M
$5.6M 1.78%
5,226
– –
TRVI icon
11
Trevi Therapeutics
TRVI
$2.49B
$4.74M 1.51%
1,263,408
– –
JNCE
12
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.63M 1.47%
529,965
– –
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.82M 1.22%
999,364
– –
PVLA
14
Palvella Therapeutics
PVLA
$1.98B
$2.72M 0.87%
9,384
– –

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2019 Portfolio in Review

As of Q4 2019, Omega Fund Management held 14 positions worth $314M, down 3% from $324M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. Omega Fund Management opened no new positions and made no exits, leaving the 14-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management added most to Replimune Group in Q4 2019, an estimated $3.17M increase.
  • Omega Fund Management's biggest Q4 2019 reduction was Gossamer Bio, cutting an estimated $8.74M.
  • Omega Fund Management's ten largest holdings make up 95% of its $314M portfolio in Q4 2019.
  • Omega Fund Management opened 0 new positions and closed 0 in Q4 2019.
  • Omega Fund Management's portfolio value fell 3% quarter-over-quarter to $314M.

Based on Omega Fund Management's 13F filing for Q4 2019, filed 13 Feb 2020.